Prednisone

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organization(s)	Biomarker(s)	Cancer type	Therapy(ies)
FDA (1)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone
FDA (1)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone
FDA (1)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone
FDA (1)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone
FDA (1)	CD30 +	Anaplastic Large Cell Lymphoma	Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone
FDA (1)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisone
FDA (1)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisone
FDA (1)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisone
FDA (1)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisone
FDA (1)	BCR::ABL1	Acute Lymphoid Leukemia	Cytarabine, Methotrexate, Ponatinib, Prednisone, Vincristine
FDA (2)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine
FDA (1)	CD20 +	Diffuse Large B-Cell Lymphoma	Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine
FDA (1)	CD20 +	Burkitt Lymphoma	Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine
FDA (1)	CD20 +	Mature B-Cell Neoplasms	Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine